Answers are grounded in this paper and cite their sources.
This Viewpoint assesses the rigor applied by the US Food and Drug Administration to the premarket clearance and postmarket surveillance of medical devices and considers potential remedies to the inherent shortcomings.
No takes yet. Share an insight, caveat, or question.
Adashi et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: